Literature DB >> 7865883

Separation of v-Src-induced mitogenesis and morphological transformation by inhibition of AP-1.

M C Frame1, K Simpson, V J Fincham, D H Crouch.   

Abstract

v-Src activity results in both morphological transformation and reentry of quiescent chick embryo fibroblasts (CEF) into cell cycle. We have previously used temperature-sensitive v-Src mutants to show that enhanced activity of cellular AP-1 in the first few hours after activation of v-Src invariably precedes the biological consequences. Here we have investigated whether the early activation of AP-1 is essential for any or all of the v-Src responses by using a mutant c-Fos that comprises the leucine zipper and a disrupted basic region. Expression of the c-Fos mutant partially reduced cellular AP-1 activity in exponentially growing cells. However, in CEF that had been made quiescent by serum deprivation, v-Src-induced stimulation of AP-1 DNA binding activity was substantially reduced. In addition, quiescent CEF stably transfected with this mutant show an impaired mitogenic response to v-Src, indicating that the AP-1 stimulation is a necessary prerequisite for cell-cycle reentry. The ability of v-Src to morphologically transform quiescent CEF was not impaired by the inhibition of AP-1 stimulation, indicating that the mitogenic and morphological consequences of v-Src have distinguishable biochemical mediators. Focal adhesion kinase, a recently identified determinant of cell morphology, undergoes a gel mobility shift, characteristic of its hyperphosphorylated state, in response to v-Src activation in cells expressing the inhibitory AP-1 protein. This provides further evidence that the pathways that regulate morphological transformation are independent of AP-1.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7865883      PMCID: PMC301144          DOI: 10.1091/mbc.5.11.1177

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  49 in total

1.  Focal adhesion kinase: an integrin-linked protein tyrosine kinase.

Authors:  M D Schaller; J T Parsons
Journal:  Trends Cell Biol       Date:  1993-08       Impact factor: 20.808

2.  Dissociation of transformation parameters using temperature-conditional mutants of Rous sarcoma virus.

Authors:  M J Weber; R R Friis
Journal:  Cell       Date:  1979-01       Impact factor: 41.582

3.  Mitogenesis induced by pp60v-src is not accompanied by increased expression of immediate early response genes.

Authors:  M J Welham; J A Wyke; A Lang; A W Wyke
Journal:  Oncogene       Date:  1990-02       Impact factor: 9.867

4.  Ectopic expression of the erythrocyte band 3 anion exchange protein, using a new avian retrovirus vector.

Authors:  S Fuerstenberg; H Beug; M Introna; K Khazaie; A Muñoz; S Ness; K Nordström; J Sap; I Stanley; M Zenke
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

5.  Characteristics of a conditional mutant of Rous sarcoma virus defective in ability to transform cells at high temperature.

Authors:  J M Biquard; P Vigier
Journal:  Virology       Date:  1972-02       Impact factor: 3.616

6.  JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain.

Authors:  B Dérijard; M Hibi; I H Wu; T Barrett; B Su; T Deng; M Karin; R J Davis
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

7.  Regulation of AP-1/DNA complex formation in vitro.

Authors:  M C Frame; N M Wilkie; A J Darling; A Chudleigh; A Pintzas; J C Lang; D A Gillespie
Journal:  Oncogene       Date:  1991-02       Impact factor: 9.867

8.  Leucine repeats and an adjacent DNA binding domain mediate the formation of functional cFos-cJun heterodimers.

Authors:  R Turner; R Tjian
Journal:  Science       Date:  1989-03-31       Impact factor: 47.728

9.  Casein kinase II is a negative regulator of c-Jun DNA binding and AP-1 activity.

Authors:  A Lin; J Frost; T Deng; T Smeal; N al-Alawi; U Kikkawa; T Hunter; D Brenner; M Karin
Journal:  Cell       Date:  1992-09-04       Impact factor: 41.582

10.  Novel tyrosine kinase substrates from Rous sarcoma virus-transformed cells are present in the membrane skeleton.

Authors:  J R Glenney; L Zokas
Journal:  J Cell Biol       Date:  1989-06       Impact factor: 10.539

View more
  7 in total

1.  The SH3 domain directs acto-myosin-dependent targeting of v-Src to focal adhesions via phosphatidylinositol 3-kinase.

Authors:  V J Fincham; V G Brunton; M C Frame
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

2.  The catalytic activity of Src is dispensable for translocation to focal adhesions but controls the turnover of these structures during cell motility.

Authors:  V J Fincham; M C Frame
Journal:  EMBO J       Date:  1998-01-02       Impact factor: 11.598

3.  Cas mediates transcriptional activation of the serum response element by Src.

Authors:  Y Hakak; G S Martin
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

4.  v-Src-induced modulation of the calpain-calpastatin proteolytic system regulates transformation.

Authors:  N O Carragher; M A Westhoff; D Riley; D A Potter; P Dutt; J S Elce; P A Greer; M C Frame
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

5.  Translocation of Src kinase to the cell periphery is mediated by the actin cytoskeleton under the control of the Rho family of small G proteins.

Authors:  V J Fincham; M Unlu; V G Brunton; J D Pitts; J A Wyke; M C Frame
Journal:  J Cell Biol       Date:  1996-12       Impact factor: 10.539

Review 6.  Src family kinases, adaptor proteins and the actin cytoskeleton in epithelial-to-mesenchymal transition.

Authors:  Maria A Ortiz; Tatiana Mikhailova; Xiang Li; Baylee A Porter; Alaji Bah; Leszek Kotula
Journal:  Cell Commun Signal       Date:  2021-06-30       Impact factor: 5.712

7.  Maintenance of the differentiated state in skeletal muscle: activation of v-Src disrupts sarcomeres in quail myotubes.

Authors:  L Castellani; M C Reedy; M C Gauzzi; C Provenzano; S Alemà; G Falcone
Journal:  J Cell Biol       Date:  1995-08       Impact factor: 10.539

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.